TG4050 AACR 2024
Category: 2024
Transgene, Nec, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
Transgene Nec and BostonGene expand collaboration
Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer
financial calendar 2024
Transgene Announces Financial Calendar for 2024
financial calendar 2024
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
Transgene and NEC extend their collaboration